Search

MSK researchers developed an artificial intelligence system to detect cancer on digitized microscope slides.

… Monday, July 15, 2019 VIDEO | 00:45 Thomas Fuchs discusses how the computer model uses artificial intelligence to analyze digitized patient slides and detect cancer. Video Details Summary Cancer pathologists can spend hours each day studying slides that may yield little useful information. A type of

Memorial Sloan Kettering Cancer Center (MSK) announces its most recent awards and appointments for the institution’s physicians, scientists, nurses, and staff.

… Tuesday, March 16, 2021 Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments: Chrysothemis Brown Receives a 2021 Parker Institute for Cancer Immunotherapy Award Chrysothemis Brown Chrysothemis (Chryssie) Brown, MBBS, PhD , was recently awarded a 2021 Parker Institute

Memorial Sloan Kettering (MSK) has named three investigators as recipients of this year’s Paul Marks Prize for Cancer Research. The award recognizes promising investigators aged 45 or younger for their efforts in advancing cancer research.

… Tuesday, September 29, 2015 Memorial Sloan Kettering (MSK) has named three investigators as recipients of this year’s  Paul Marks Prize for Cancer Research . The award recognizes promising investigators aged 45 or younger for their efforts in advancing cancer research. The winners are Bradley Bernstein

Two of the year's top five cancer research advances cited by the American Society of Clinical Oncology were led by Memorial Sloan Kettering investigators.

… Monday, February 6, 2012 Summary Two of the year’s top five cancer research advances cited by the American Society of Clinical Oncology were led by Memorial Sloan Kettering investigators. Two of the top five advances in cancer research for 2011 cited by the annual progress report of the American Society

Clinicians and scientists at MSK continue to investigate new ways to improve outcomes for patients with thyroid cancer. Recent research insights from MSK thyroid cancer experts include, the safety and feasibility of active surveillance for certain patients, the identification of mutation profiles of subgroups, recommendations for future clinical trials of redifferentiation therapy, and study results showing that larotrectinib may be beneficial for treatment-naïve patients with NTRK fusion-positive thyroid cancer.

… Thursday, July 10, 2025 Clinicians and scientists at Memorial Sloan Kettering Cancer Center (MSK) continue to investigate new ways to improve outcomes for patients with thyroid cancer. Recent research insights from MSK thyroid cancer experts include: the safety and feasibility of active surveillance

Treating advanced melanoma patients with either a combination of the immunotherapy drugs nivolumab and ipilimumab or nivolumab alone significantly increases progression-free survival over using ipilimumab alone, according to new findings from researchers at Memorial Sloan Kettering simultaneously presented today at the American Society of Clinical Oncology annual meeting and published online in the New England Journal of Medicine.

… Sunday, May 31, 2015 Treating advanced melanoma patients with either a combination of the immunotherapy drugs nivolumab (Opdivo™) and ipilimumab (Yervoy™) or nivolumab alone significantly increases progression-free survival (PFS) over using ipilimumab alone, according to new findings from researchers

Memorial Sloan Kettering researchers have found a way to restore innate immune defense in the intestines and enhance resistance to a potentially harmful antibiotic-resistant bacterium.

… Monday, December 1, 2008 Summary Memorial Sloan Kettering researchers have found a way to restore innate immune defense in the intestines and enhance resistance to a potentially harmful antibiotic-resistant bacterium. Infection by antibiotic-resistant bacteria is a dangerous complication of broad-spectrum

Computational biologist Thomas Norman, PhD, of Memorial Sloan Kettering’s (MSK) Sloan Kettering Institute (SKI) has been named one of 53 recipients of the prestigious 2020 National Institutes of Health (NIH) Director’s New Innovator Award. As part of the award, Dr. Norman will receive $1.5 million in direct costs upfront in the first year of a five-year award. 

… Tuesday, October 6, 2020 Computational biologist  Thomas Norman, PhD , of Memorial Sloan Kettering’s (MSK) Sloan Kettering Institute (SKI) has been named one of 53 recipients of the prestigious 2020 National Institutes of Health (NIH) Director’s New Innovator Award. As part of the award, Dr. Norman will

Kravis WiSE promotes gender equity in science by providing stable funding and professional support for women in science at Memorial Sloan Kettering Cancer Center.

… Wednesday, March 6, 2024 Memorial Sloan Kettering Cancer Center (MSK) is proud to announce four  Sloan Kettering Institute  (SKI) researchers have been named 2024  Marie-Josée Kravis WISE  fellowship grant recipients. Kravis WiSE was established in 2020, and is now in its fifth class. Kravis WISE remains

Recent findings by Memorial Sloan Kettering investigators suggest it might be possible to improve the effectiveness of chemotherapy for breast cancer by combining the treatment with a new type of drug called a cathepsin inhibitor.

… Friday, December 2, 2011 Summary Recent findings by Memorial Sloan Kettering investigators suggest it might be possible to improve the effectiveness of chemotherapy for breast cancer by combining the treatment with a new type of drug called a cathepsin inhibitor. Pictured: Genes & Development Journal